 |
NHMRC Clinical Trials Centre |
 |
 |
 |
 |
 |
 |
 |
 |
||
| Cancer trials | |
| Support for cancer trials | |
| Breast cancer | |
| Gastrointestinal cancer | |
| Germ-cell cancer | |
| Gynaecological cancer | |
| Lung cancer | |
| Brain cancer | |
| Other cancer trials | |
Trials > Cancer > Gastrointestinal cancer
| Gastrointestinal cancer trials | |||||||||
|
|||||||||
| Trials open to recruitment | |||||||||
| Da Vinci: Phase II-III trial of irinotecan versus irinotecan + De Gramont schedule 5-fluorouracil and folinic acid in patients with previously treated metastatic colorectal cancer (AG103CR) | Quasar 2: Phase III study of capecitabine and bevacizumab as adjuvant treatment of colorectal cancer | ||||||||
|
AGITG study Participants Treatment Outcome measures Recruitment target: 100 Funding: Pfizer Australia Status: open to recruitment Recruitment target: 100 |
Oxford Clinical Trials Office (OCTO)–AGITG study Participants Treatment Outcome measures Recruitment target: 120 Funding: Roche Products (Australia) Status: open to recruitment Recruitment target: 120 |
||||||||
| Phase III adjuvant trial in pancreatic cancer comparing: 5-fluorouracil + D-L folinic acid with gemcitabine or no adjuvant treatment (ESPAC-3) | Gastrointestinal stromal tumors (GIST) expressing KIT receptor: adjuvant imatinib mesylate (Glivec) versus no further therapy after surgery (EORTC 62024) | ||||||||
European Study Group for Pancreatic Cancer (ESPAC)–AGITG study Participants Treatment Outcome measures Recruitment target: 990 (150 from Australia and New Zealand) Funding: National Health and Medical Research Council (NHMRC) Status: open to recruitment Recruitment target: 150 |
European Organisation for Research and Treatment of Cancer (EORTC)–AGITG study
Participants Treatment Outcome measures Recruitment target: 990 (80 from Australia and New Zealand) Funding: State cancer councils, Novartis Pharmaceuticals Australia, EORTC Status: open to recruitment |
||||||||
| Back to top | Back to top | ||||||||
| Pending trials | |||||||||
| Phase III study of BMS-582664 with cetuximab versus placebo with cetuximab in patients previously treated with combination chemotherapy for metastatic colorectal carcinoma (CO.20) | ATTAX 3: Randomised phase II study evaluating triplet chemotherapy regimens incorporating cisplatin, fluoropyrimidine and either weekly docetaxel or epirubicin plus or minus panitumumab in advanced oesophagogastric cancer | ||||||||
National Cancer Institute of Canada (NCIC)-AGITG study Participants Treatment Outcome measures Recruitment target: 370 Funding: Bristol-Myers Squibb and NCIC Status |
AGITG study Participants Treatment Outcome measures Recruitment target: 100 Status |
||||||||
| DECO: Randomised phase II trial of weekly docetaxel (Taxotere) chemoradiotherapy with or without cetuximab (Erbitux) in the treatment of localised resectable cancer of the oesophagus | Resectable gastric study: Randomised phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for gastric cancer | ||||||||
|
AGITG study Participants Treatment Outcome measures Recruitment target: 80 Funding: Merck Serono Australia Status |
ITrans-Tasmanian Oncology Group (TROG)–AGITG study
Participants Treatment • postoperative chemotherapy Outcome measures Recruitment target: 140 Status |
||||||||
| Register: Phase II study in adults with newly diagnosed gastrointestinal stromal tumour (GIST) incorporating risk-stratification and sequential dose-escalation of imatinib in patients with tumours containing an exon 9 mutation and subsequent addition of nilotinib in poor responders | PETACC 6: Phase III randomised study of preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs capecitabine alone in rectal cancer | ||||||||
AGITG study Participants Treatment Outcome measures Recruitment target: 100 Status |
European Organisation for Research and Treatment of Cancer (EORTC)–AGITG study Participants Treatment Outcome measures Recruitment target: 100 Funding: Cancer Australia Status |
||||||||
| Back to top | Back to top | ||||||||
| Trials closed to recruitment | |||||||||
| MAX: a randomised phase II-III study to evaluate the role of Mitomycin C [mitomycin], Avastin [bevacizumab] and Xeloda [capecitabine] in patients with untreated metastatic colorectal cancer (AG0501CR) | EORTC 40983: Pre- and postoperative chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin compared with surgery alone for resectable liver metastases of colorectal origin | ||||||||
Investigator-initiated intergroup trial: AGITG Outcome measures Recruitment: 471 Funding: Roche Status: In follow-up |
Investigator-initiated
intergroup trial: AGITG and EORTC Status: Open to recruitment Participants Patients with potentially resectable liver metastases from colorectal origin. Patients will not have received prior therapy for advanced disease. Outcome measures Funding: EORTC and AGITG Status: In follow-up |
||||||||
| Back to top | Back to top | ||||||||
ATTAX: Phase II study evaluating a weekly schedule of docetaxel with cisplatin and 5-fluorouracil or capecitabine (AG0603G) |
ABC: Phase II trial of gemcitabine in fixed-dose-rate infusion compared with cisplatin in patients with biliary tract carcinoma (AG0403BT) | ||||||||
|
AGITG study Participants Treatment Outcome measures Recruitment: 106 Funding: Sanofi Aventis (Australia) and Roche Products (Australia) Status: In follow-up |
AGITG study Participants Treatment Outcome measures Recruitment: 50 Funding: Eli Lilly Australia and NHMRC Clinical Trials Centre Status: In follow-up |
||||||||
| Back to top | Back to top | ||||||||
| CO.17: Phase III study of cetuximab and best supportive care versus best supportive care in patients with pretreated metastatic epidermal-growth-factor-receptor (EGFR-positive colorectal carcinoma) | ATTAX 2: Phase II study of cetuximab plus docetaxel in docetaxel-refractory patients with EGFR-positive cancer (AG0603G) | ||||||||
National Cancer Institute of Canada (NCIC)-AGITG study Participants Treatment Outcome measures Recruitment: 252 Funding: Bristol-Myers Squibb and NCIC Status: In follow-up |
AGITG study Participants Treatment Outcome measures Recruitment: 38 Funding: Alphapharm (Australia) Status: In follow-up |
||||||||
| Back to top | Back to top | ||||||||
| Oral uracil/ftorfur plus leucovorin compared with 5-fluorouracil plus leucovorin in the treatment of patients with stages II and III carcinoma of the colon (C-06) | 5-fluorouracil plus leucovorin and oxaliplatin compared with 5-fluorouracil plus leucovorin for the treatment of patients with stages II and III carcinoma of the colon (C-07) | ||||||||
| Investigator-initiated
intergroup trial: AGITG and NSABP Status: closed to recruitment Participants Patients with stage II and stage III adenocarcinoma of the colon, no metastatic disease and a life expectancy of at least 10 years (excluding the diagnosis of cancer) Outcome measures • disease-free survival • survival • quality of life • prognostic significance of genetic and biologic markers and their relationships with tumour characteristics Recruitment: 11 Funding: NSABP and NCI
|
Investigator-initiated
intergroup trial: AGITG and NSABP Funding: NSABP, NCI, Sanofi |
||||||||
| Back to top | Back to top | ||||||||
| Phase III randomised, intergroup, international trial assessing the clinical activity of STI-571 at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) expressing the KIT receptor tyrosine kinase (CD117) (EORTC 62005) | Gofurtgo: Phase II study of fixed-dose rate gemcitabine–oxaliplatin integrated with concomitant 5-fluorouracil and radiotherapy to treat localised pancreatic cancer (AG0503P) | ||||||||
European Organisation for Research and Treatment of Cancer (EORTC)–AGITG study Outcome measures Status: closed Recruitment target: 600 Funding: Novartis |
AGITG study Participants Treatment Outcome measures Recruitment: 48 Funding: Sanofi-Aventis Group (Australia) and NHMRC Clinical Trials Centre Status: In follow-up |
||||||||
| Back to top | |||||||||
